We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.


The Oncotype MAP™ Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. Using next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the test identifies actionable genomic alterations within 3-5 business days and with small tissue sample sizes.1 The test guides timely discussions and decisions, while helping physicians understand a patient’s tumor profile to recommend targeted therapies or clinical trials.


1Internal Data on File. Exact Sciences Corporation. Madison, WI. Turnaround time based on qualified sample receipt.